Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN5A | Q14524 | 15/20 | 0.54 |
| ▸ | SCN1A | P35498 | 2/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.54 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936522 | 0.89 | SCN5A (0.49) | SCN5ASCN1ASCN2AMAPK14 | |
| SCHEMBL19056334 | 0.86 | SCN5A (0.58) | SCN5ASCN1ASCN2AMAPK14EPHX2 | |
| SCHEMBL937600 | 0.85 | SCN5A (0.57) | SCN5ASCN1ASCN2AMAPK14 | |
| SCHEMBL937017 | 0.85 | SCN5A (0.72) | SCN5ASCN1ASCN2A | |
| SCHEMBL936964 | 0.80 | SCN5A (0.65) | SCN5ASCN1ASCN2AMAPK14 | |
| SCHEMBL19056335 | 0.79 | SCN5A (0.50) | SCN5ASCN1ASCN2A | |
| SCHEMBL2721728 | 0.78 | CA12 (0.59) | EPHX2 | |
| SCHEMBL19056329 | 0.77 | SCN5A (0.53) | SCN5ASCN1ASCN2AMAPK14 | |
| SCHEMBL937444 | 0.77 | SCN5A (0.58) | SCN5ASCN1ASCN2A | |
| SCHEMBL936033 | 0.76 | SCN5A (0.57) | SCN5ASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2464645-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-07-05 | — | — | EP | claimed |
| US-8952034-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | claimed |
| US-8754103-B2 | — | — | 2014-06-17 | — | — | US | claimed |
| EP-2464645-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Palo Alto, Inc. (US) | 2012-06-20 | — | — | EP | claimed |
| WO-2011014462-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-02-03 | — | — | WO | claimed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | claimed |
| EP-2464645-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9371329-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-8952034-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8754103-B2 | — | — | 2014-06-17 | — | — | US | disclosed |
| EP-2464645-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Palo Alto, Inc. (US) | 2012-06-20 | — | — | EP | disclosed |
| WO-2011014462-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-02-03 | — | — | WO | disclosed |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303158-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | SCN5A 52/4885SCN1A 55/4885SCN2A 72/4885 |
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | SCN5A 52/4885SCN1A 55/4885SCN2A 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.